82415-84-7

Basic information

• Product Name: 3(2H)-benzofuranone, oxime, (3Z)-
• Synonyms: (3Z)-1-benzofuran-3(2H)-one oxime;3(2H)-benzofuranone, oxime, (3Z)-;(Z)-benzofuran-3(2H)-one oxime
• CAS NO: 82415-84-7
• Molecular Formula: C₈H₇NO₂
• Molecular Weight: 149.14668
• Mol File: 82415-84-7.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3(2H)-benzofuranone, oxime, (3Z)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-benzofuranone, oxime, (3Z)-(82415-84-7)
• EPA Substance Registry System: 3(2H)-benzofuranone, oxime, (3Z)-(82415-84-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 82415-84-7(Hazardous Substances Data)

Upstream product

• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 335164-91-5 2-[(phenylseleno)methoxy]benzaldehyde 

Downstream Products

• 5735-53-5 1,4-benzoxazine 
• 888730-48-1 2,6-dichloro-4-(2,3-dihydro-1,4-benzoxazin-4-ylcarbonyl)phenol 
• 1410748-15-0 N-benzyl-2,3-dihydrobenzofuran-3-amine 
• 1410747-83-9 methyl benzyl(2,3-dihydrobenzofuran-3-yl)carbamate 
• 1410747-77-1 tert-butyl benzyl(2,3-dihydrobenzofuran-3-yl)carbamate 
• 109926-35-4 dihydro-2,3 benzofurannamine-3 
• 208711-58-4 benzofuran-3(2H)-one O-methyl oxime 
• 82415-85-8 2-Chloro-benzofuran-3-one 

Relevant articles and documents

ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor

ERK INHIBITORS

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

Development of potent inhibitors of pyocyanin production in pseudomonas aeruginosa

The development of new approaches for the treatment of antimicrobial-resistant infections is an urgent public health priority. The Pseudomonas aeruginosa pathogen, in particular, is a leading source of infection in hospital settings, with few available treatment options. In the context of an effort to develop antivirulence strategies to combat bacterial infection, we identified a series of highly effective small molecules that inhibit the production of pyocyanin, a redox-active virulence factor produced by P. aeruginosa. Interestingly, these new antagonists appear to suppress P. aeruginosa virulence factor production through a pathway that is independent of LasR and RhlR.